1Kang PM, Landan A J, Eberhardt RT, et al. Angiotensin Ⅱ receptor antagonists: a new approach to blockade of the renin angiotensin system Am Heart J, 1994, 127:1388
2Francis GS, Mcdonald KM. Congestive heart failure, mechanism, physiologic derangement and theraphy. In: Signh BN,Dzan V J, Vanhoutte PM eds. Cardiovascular pharmacology and therapeutics, New York: Churchill Livingstone, 1994. 765-803
3Crozier L, Kram H, Awan N, et al. Losartan in heart failure hemodynamic effects and tolerability. Circulation, 1995, 91(3)'; 691
4Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med, 1994, 330(20): 1431
5Ling Q. Regression of cardiohypertrophy and myosin isozyme patterns by losartan and catopril in renovascular hypertensive rats.Acta Pharmacol Sin, 1994, 15(3): 206
7Sudhir k, Macgregor JS, Gupta M, et al. Effect of selective angiotensin Ⅱ receptor antagonisin and angiotensin converting enzyme inhibition on the coronary vasculation in vivo-intravascular two-dimensional and Doppler ultrasound studies. Circulation, 1993,87(3): 931
8Gottieb SS, Dickstein K, Fleck F, et al. Hemodynamic and neurohormonal effects of the angiotensin Ⅱ antagonist losartan in patients with congestive heart failure. Circulation, 1993, 88(part 1):1602
9Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan verus captopril in patients over 65 with heart failure (Evaluation of losartan in the elderly study, ELITE). Lancet, 1997,349: 747
10Goldberg AI, Duhlay MC, Sweet CS, Safety and tolerability of losartan compared with atenol felodipine and angiotensin converting enzyme inhibitors. J Hypertens, 1995, 13(suppl 1): 77
